Diabetes, Vol 46, Issue 7 1207-1213, Copyright © 1997 by American Diabetes Association

ARTICLES

Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients

A Caixas, J Ordonez-Llanos, A de Leiva, A Payes, R Homs and A Perez
Endocrinology Department, Hospital de Sant Pau, Universitat Autnoma de Barcelona, Spain.

Small dense LDL particles (B phenotype) are considered to be more atherogenic than large buoyant LDL particles. The influence of glycemic control on LDL particle size and density is still under debate. The aim of this study was to determine LDL subfraction phenotype in both IDDM and NIDDM patients in poor glycemic control compared with that of respective matched control groups. In addition, we evaluated the effect of a 3-month period of optimized glycemic control on this parameter. Thirty-seven IDDM patients and 33 NIDDM patients, together with two respective age-, sex-, and BMI-matched control groups were studied. Non-A phenotype prevalence in IDDM patients before (19%) and after blood glucose optimization (11%) was similar to that of their control group (12%). However, NIDDM patients displayed a higher proportion of the non-A phenotype (51%) than did the control group (28%), but it became closer (30%, P < 0.05) after glycemic control improved. All subjects with non-A phenotype that changed to A phenotype showed triglyceride levels below 1.63 mmol/l and a greater decrease in HbA1c than did subjects whose phenotype did not change (4.9 +/- 1.5 vs. 3.1 +/- 1.4%, P < 0.05). A higher proportion of small dense LDL was observed in NIDDM women than in nondiabetic women (LDL5 10.0 +/- 4.8 vs. 6.3 +/- 1.5%, LDL6 6.1 +/- 2.2 vs. 4.2 +/- 0.8%, P < 0.05) during both stages of glycemic control, but no differences were observed between NIDDM and nondiabetic men. In conclusion, these findings provide new evidence for the relevance of near-normal glycemic control in the prevention of macrovascular disease and could contribute to an explanation of the loss of protection for cardiovascular disease in diabetic women.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Vehkavaara and H. Yki-Jarvinen 3.5 Years of Insulin Therapy With Insulin Glargine Improves In Vivo Endothelial Function in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 325 - 330. [Abstract] [Full Text]

				A. M. Wagner, O. Jorba, R. Bonet, J. Ordonez-Llanos, and A. Perez Efficacy of Atorvastatin and Gemfibrozil, Alone and in Low Dose Combination, in the Treatment of Diabetic Dyslipidemia J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3212 - 3217. [Abstract] [Full Text] [PDF]

				J. L. Sanchez-Quesada, S. Benitez, C. Otal, M. Franco, F. Blanco-Vaca, and J. Ordonez-Llanos Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects J. Lipid Res., May 1, 2002; 43(5): 699 - 705. [Abstract] [Full Text] [PDF]

				J. L. Sanchez-Quesada, A. Perez, A. Caixas, M. Rigla, A. Payes, S. Benitez, and J. Ordonez-Llanos Effect of Glycemic Optimization on Electronegative Low-Density Lipoprotein in Diabetes: Relation to Nonenzymatic Glycosylation and Oxidative Modification J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3243 - 3249. [Abstract] [Full Text] [PDF]

				A. A. Rivellese, L. Patti, G. Romano, F. Innelli, L. Di Marino, G. Annuzzi, M. Iavicoli, G. A. Coronel, and G. Riccardi Effect of Insulin and Sulfonylurea Therapy, at the Same Level of Blood Glucose Control, on Low Density Lipoprotein Subfractions in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4188 - 4192. [Abstract] [Full Text]

				A. Perez, A. M. Wagner, G. Carreras, G. Gimenez, J. L. Sanchez-Quesada, M. Rigla, J. A. Gomez-Gerique, J. M. Pou, and A. de Leiva Prevalence and Phenotypic Distribution of Dyslipidemia in Type 1 Diabetes Mellitus: Effect of Glycemic Control Arch Intern Med, October 9, 2000; 160(18): 2756 - 2762. [Abstract] [Full Text] [PDF]

				S. Vehkavaara, S. Makimattila, A. Schlenzka, J. Vakkilainen, J. Westerbacka, and H. Yki-Jarvinen Insulin Therapy Improves Endothelial Function in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 545 - 550. [Abstract] [Full Text] [PDF]

				Y. Kako, L.-S. Huang, J. Yang, T. Katopodis, R. Ramakrishnan, and I. J. Goldberg Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice: effects on lipoproteins and atherosclerosis J. Lipid Res., December 1, 1999; 40(12): 2185 - 2194. [Abstract] [Full Text] [PDF]

				J. L. Dixon, J. D. Stoops, J. L. Parker, M. H. Laughlin, G. A. Weisman, and M. Sturek Dyslipidemia and Vascular Dysfunction in Diabetic Pigs Fed an Atherogenic Diet Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2981 - 2992. [Abstract] [Full Text] [PDF]

				B. Guerci, H. Antebi, L. Meyer, V. Durlach, O. Ziegler, J.-P. Nicolas, L.-G. Alcindor, and P. Drouin Increased Ability of LDL from Normolipidemic Type 2 Diabetic Women to Generate Peroxides Clin. Chem., September 1, 1999; 45(9): 1439 - 1448. [Abstract] [Full Text] [PDF]